Health Care & Life Sciences » Biotechnology | TetraLogic Pharmaceuticals Corp.

TetraLogic Pharmaceuticals Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2011
2012
2013
2014
2015
Cost of Goods Sold (COGS) incl. D&A
214.80
154.00
99.60
126.00
188.00
Gross Income
214.80
154.00
99.60
126.00
188.00
SG&A Expense
18,654.50
16,017.90
17,891.30
30,687.60
38,312.30
EBIT
18,869.40
16,171.90
17,990.90
30,813.60
38,500.30
Unusual Expense
48.50
43.10
807.30
1,898.80
4,932.00
Non Operating Income/Expense
-
-
-
0.20
-
Interest Expense
6.80
73.40
2,767.40
3,359.40
6,384.30
Pretax Income
18,919.70
16,199.50
19,950.40
35,959.00
49,724.10
Consolidated Net Income
18,919.70
16,199.50
19,950.40
35,959.00
49,724.10
Net Income
18,919.70
16,199.50
19,950.40
35,959.00
49,724.10
Net Income After Extraordinaries
18,919.70
16,199.50
19,950.40
35,959.00
49,724.10
Net Income Available to Common
22,188.80
16,199.50
23,200.30
35,959.00
49,724.10
EPS (Basic)
1.59
1.52
1.05
1.63
2.10
Basic Shares Outstanding
13,921.60
10,628.70
22,199.30
22,290.10
23,692.30
EPS (Diluted)
1.59
1.52
1.05
1.63
2.10
Diluted Shares Outstanding
13,921.60
10,628.70
22,199.30
22,351.70
23,730.40
EBITDA
18,654.50
16,017.90
17,891.30
30,687.60
38,312.30
Non-Operating Interest Income
4.90
2.70
0.60
112.70
92.50
Preferred Dividends
3,269.20
-
3,249.90
-
-

About TetraLogic Pharmaceuticals

View Profile
Address
343 Phoenixville Pike
Malvern Pennsylvania 19355
United States
Employees -
Website http://www.tetralogicpharma.com
Updated 07/08/2019
TetraLogic Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing novel small molecule therapeutics in oncology and infectious diseases. It products include Birinapant, and SHAPE. The company was founded by John M.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.